|Friday, 23 March 2018, 14:41 HKT/SGT|
|Antibody HUMIRA in the Treatment of Patients who have had an Inadequate Response to Conventional Therapy for Pustular Psoriasis|
TOKYO, Mar 23, 2018 - (JCN Newswire) - AbbVie GK and Eisai Co., Ltd. today announced the additional approval for a new indication of HUMIRA (generic name: adalimumab (recombinant), "HUMIRA"), a fully human anti-TNF-alpha monoclonal antibody formulation, in the treatment of patients who have had an inadequate response to conventional therapy for pustular psoriasis. With this approval, HUMIRA has been approved for 10 indications in Japan.
The approval of this additional indication is based on the results of a Phase 3 study in Japanese patients. This study examined efficacy and safety in Japanese patients diagnosed with generalized pustular psoriasis (GPP) who have had an inadequate response to conventional therapy (e.g., etretinate and cyclosporine). Among the patients treated with HUMIRA in the open-label clinical trial, 70% (n=7/10) achieved a clinical response (improvement or reduction of skin score relative to the baseline) after 16 weeks of treatment(1). Adverse reactions were observed in 30% (n= 3/10) of patients, such as eosinophilia, bacterial colitis, herpes zoster infection, and eye contusion (respective incidence was 10% (n=1/10) each). No new safety risks were identified for patients with GPP treated with HUMIRA(2).
Pustular psoriasis is a disease designated as an "Intractable Disease" by the Japan Ministry of Health, Labor and Welfare (MHLW), and the major symptoms include fever, general malaise, redness, swelling of limbs, and pustules on the whole body. The number of patients receiving intractable disease benefits due to this condition is reported to be 2,072 nationwide, and this has increased by more than 200 patients in the past 5 years (as of the end of fiscal 2016)(3). The treatment guideline(4) for pustular psoriasis includes anti-TNF-alpha antibody formulations as a treatment option alongside etretinate, methotrexate, and cyclosporine.
"The research and clinical technology on GPP have been evolving dramatically in the recent years. However, further progress is needed considering severity of the disease. The approval of this indication for HUMIRA has been highly anticipated by healthcare professionals as well as patients," said Hidemi Nakagawa, M.D., Chair, Department of Dermatology, The Jikei University School of Medicine.
"We are pleased to provide the new treatment option to patients with pustular psoriasis," said James Feliciano, President of AbbVie Japan. "More than 1 million patients have been already treated with HUMIRA in more than 100 countries. This is the 10th indication of HUMIRA approved on the 10th anniversary of its first launch in Japan. We continue to contribute to patients living with inflammatory autoimmune diseases by pursuing new discoveries and better outcomes that go beyond current standards of care."
Mr. Hideki Hayashi, Eisai Representative Corporate Officer, Japan Business and CIO commented, "Eisai will continue to provide healthcare professionals with information and promote proper clinical use, aiming to fulfill the unmet medical needs in the treatment of GPP and maximise benefits for patients and their families."
(1) Drug Information of HUMIRA
(2) Data on file
(3) Intractable Disease Information Center (http://www.nanbyou.or.jp/)
(4) Pustular Psoriasis (Generalized) Guildeline 2014, GPP Clinical Guideline Committee, Japanese Dermatological Association, Japanese Dermatological Association Journal: 125 (12), 2211-2257,2015
AbbVie is a global, research-driven biopharmaceutical company committed to developing innovative advanced therapies for some of the world's most complex and critical conditions. The company's mission is to use its expertise, dedicated people and unique approach to innovation to markedly improve treatments across four primary therapeutic areas: immunology, oncology, virology and neuroscience. In more than 75 countries, AbbVie employees are working every day to advance health solutions for people around the world. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on Twitter, Facebook or LinkedIn.
For more information, please visit www.abbvie.com/HCV.
Eisai Co., Ltd. is a leading global research and development-based pharmaceutical company headquartered in Japan. We define our corporate mission as "giving first thought to patients and their families and to increasing the benefits health care provides," which we call our human health care philosophy. With approximately 10,000 employees working across our global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to realize our human health care philosophy by delivering innovative products in various therapeutic areas with high unmet medical needs, including Oncology and Neurology.
As a global pharmaceutical company, our mission extends to patients around the world through our investment and participation in partnership-based initiatives to improve access to medicines in developing and emerging countries.
For more information about Eisai Co., Ltd., please visit www.eisai.com.
Public Relations Department,
Eisai Co., Ltd.
Mar 23, 2018 14:41 HKT/SGT
Eisai (TSE: 4523)
Topic: Press release summary
From the Asia Corporate News Network
Copyright © 2018 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
|Sept 5, 2018 14:28 HKT/SGT|
Eisai And Merck & Co. Announce China NMPA Approval of First Approval for LENVIMA (Lenvatinib) for Treatment of Unresectable HCC|
|Sept 3, 2018 14:50 HKT/SGT|
Eisai Receives Approval for Partial Label Change for Vascular Embolization Device DC Bead|
|Aug 30, 2018 09:36 HKT/SGT|
Eisai's LENVIMA (LENVATINIB) Capsules Approved for First-Line Treatment of Unresectable Hepatocellular Carcinoma (HCC) in South Korea|
|Aug 29, 2018 10:25 HKT/SGT|
Biogen and Eisai Report Data from Long-Term Extension Phase 1b Study of Investigational Alzheimer's Disease Treatment Aducanumab|
|Aug 28, 2018 09:11 HKT/SGT|
Eisai: Long-Term Cardiovascular Outcomes Data for Anti-Obesity Agent BELVIQ |
|Aug 23, 2018 08:00 HKT/SGT|
Eisai: European Commission Grants Marketing Authorization for LENVIMA (Lenvatinib) |
|July 31, 2018 14:13 HKT/SGT|
Eisai Signs Collaboration Agreement for Anti-Obesity Agent Lorcaserin in China to CY Biotech|
|July 31, 2018 10:27 HKT/SGT|
Eisai and Merck & Co., Inc., Kenilworth, N.J., U.S.A. Announce U.S. FDA Grants Breakthrough Therapy Designation for LENVIMA|
|July 26, 2018 10:34 HKT/SGT|
Eisai and Biogen Announce Detailed Results of Phase II Clinical Study of BAN2401 in Early Alzheimer's Disease at AAIC 2018|
|July 26, 2018 08:01 HKT/SGT|
Eisai and Biogen Present Detailed Results from Phase II Clinical Study of Elenbecestat in MCI and Mild to Moderate Alzheimer's Disease at AAIC 2018|
|More news >>|